Related Experiment Video
Updated: May 28, 2026
07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Systemic Infliximab Is Efficacious for the Control of Pediatric Uveitis Including in Adalimumab-Refractory Patients
Ian R Reekie1, Laura Ramm1, Eslam Al-Abadi1
1Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Summary
Infliximab infusion effectively treats pediatric non-infectious uveitis. It serves as a valuable second-line therapy for children unresponsive to adalimumab, offering improved disease control.
Area of Science:
- Ophthalmology
- Immunology
- Pediatrics
Background:
- Non-infectious uveitis in children can lead to vision loss.
- Anti-tumor necrosis factor (TNF) therapies are used for refractory cases.
- Adalimumab is a common first-line anti-TNF agent.
Purpose of the Study:
- To evaluate the efficacy of infliximab via intravenous infusion.
- To assess infliximab as a second-line treatment for pediatric non-infectious uveitis.
- To determine outcomes in patients with inadequate response to adalimumab.
Main Methods:
- Retrospective study design.
- Analysis of patient data receiving infliximab for non-infectious uveitis.
- Inclusion of patients previously treated with adalimumab.
Main Results:
- Infliximab demonstrated efficacy in treating pediatric non-infectious uveitis.
- Patients previously treated with adalimumab showed positive responses to infliximab.
- Intravenous infliximab provided disease control in a challenging patient group.
Conclusions:
- Infliximab is an effective treatment option for pediatric non-infectious uveitis.
- Infliximab serves as a crucial second-line therapy when adalimumab fails.
- Intravenous infliximab offers a viable therapeutic strategy for refractory cases.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...